Junson Capital is a multi-strategy single-family office founded by Longfor Properties co-founder Cai Kui. Headquartered in Hong Kong with offices in New York, Singapore, and Palo Alto, it manages over $5 billion in assets across public markets, private equity, venture capital, real estate, and alternative assets.
33% of their portfolio is in Healthcare. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-b (58% of deals). Average disclosed round size is $44.0M (across 11 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Team
Jessie Gong
Managing Director, Head of Alternative Investments
Keyan Li
Investment Director
Wei Shen
Head of Principal Investment
Lily Sanders
Vice President
Bingdong Zhao
Real Estate Investment
Daniel X.
Senior Investment Manager
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Butterfly Medical | Series C | $21M | May 2026 |
 BridGene | Series B | $28M | Jan 2026 |
 Full-Life Technologies | Series C | $50M | Sep 2025 |
| Full-Life Technologies | Series B | $47.3M | Jan 2024 |
 Allotex | Series B | — | Nov 2023 |
 Corsair Pharma | Series B | $23M | Sep 2023 |
| BridGene | Series B | $38.5M | Jul 2022 |
 Accuragen | Unknown | $40M | Jun 2016 |
| Accuragen | Series B | $40M | Jan 2016 |
 Ansun Biopharma | Series B | $80M | — |
 Wibotic | Series A | $5.7M | — |
| Full-Life Technologies | Series D | $110M | — |
Top Co-Investors
Last updated: 20 October 2026